AndersonG. H., SreetenD. H. P., DalakosT. G.: Pressor response to l-Sar-8-Ala-Angiotensin-II (Saralasin) in hypertensive patients. Circ. Res.40; 243–250 (1977).
2.
CaseD. B., WallaceJ. M., KeimH. J., SealeyJ. E., LaraghJ. H.: Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin-II, for evaluating the renin and sodium factors in hypertensive patients. Amer J Med‘ 60; 825–836 (1976).
3.
MarksL. S., MaxwellM. H., SmithR. B., CahillP. J., KaufmanJ. J.: Detection of renovascular hypertension: saralasin test versus renin determinations. J. Urol., 116; 406–409 (1976).
4.
StreetenD. H., CastellianA. W., MicalizziE. R., DalakosT., AndersonG. H., FreibergJ. M., KeenanR. E.: Saralasin (l-Sar-8-Ala-Angiotensin-II): pharmacology and clinical use in angiotensindependent hypertension. Contr. Nephrol., vol. 3, pp. 52–70, Karger Verlag, Basel 1976.
5.
ThomasR. O., BallS. G., LeeM. R.: Failure of Saralasin to predict a response to surgery in renovascular hypertension. Lance., 2; 724–726 (1977)
6.
WilsonH. M., WilsonJ. P., SlatonP. E., FosterJ. H., LiddleG. W., HollifieldJ. W.: Saralasin infusion in the recognition of renovascular hypertension Ann. Intern. Med., 87; 36–42 (1977).